- In January 2022, Sun Pharma had announced the launch of dry eye treatment product named Cequa in Canada. It is the first dry eye disease treatment that is delivered with nanomicellar (NCELL) technology. This technology enhances the bioavailability as well as physiochemical stability of cyclosporine to raise ocular tissue penetration.
Frequently Asked Questions
The market is segmented based on Segmentation, By Product Type (Tear stimulators, Artificial Tears, Secretagogue, Others), Dosage Type (Liquid, Semi-solid, Others), Drug Class (Lubricating Agent, Cholinergics, Anti-Inflammatory, Anti-Infectives, Anti-Allergics, Others), Dose (Unit dose, Multi-dose), Medication Type (Prescription (Rx) Drugs, Over The Counter (OTC) Drugs), Container Type (Unit-Dose Vials, Bottles, Tubes), Packaging Type (Plastic, Aluminium, Glass), Type (Brands, Generics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics, Others) – Industry Trends and Forecast to 2032
.
The Global Dry Eye Syndrome Market size was valued at USD 5.19 USD Billion in 2024.
The Global Dry Eye Syndrome Market is projected to grow at a CAGR of 7.3% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
